drug_name event_name drug_id event_id drug_and_event_name
3 Chlorthalidone Chronic bronchitis 1395058 255841 Chlorthalidone & Chronic bronchitis 
## Chronograph ##

## Basic demographic table##
1: DEC cohort n Percentage 2: Drug cohort n Percentage 3: Event cohort n Percentage 4: All drugs cohort n Percentage
Total 101 100 Total 1000 100 Total 721 100 Total 1000 100
Sex gender = FEMALE 56 55 Sex gender = FEMALE 594 59 Sex gender = FEMALE 426 59 Sex gender = FEMALE 546 55
gender = MALE 45 45 gender = MALE 406 41 gender = MALE 295 41 gender = MALE 454 45
Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0
(20,30] 0 0 (20,30] 4 0 (20,30] 2 0 (20,30] 6 1
(30,40] 6 6 (30,40] 19 2 (30,40] 17 2 (30,40] 13 1
(40,50] 3 3 (40,50] 66 7 (40,50] 24 3 (40,50] 44 4
(50,60] 10 10 (50,60] 75 8 (50,60] 38 5 (50,60] 58 6
(60,70] 26 26 (60,70] 201 20 (60,70] 156 22 (60,70] 222 22
(70,80] 33 33 (70,80] 340 34 (70,80] 254 35 (70,80] 390 39
(80,90] 19 19 (80,90] 241 24 (80,90] 178 25 (80,90] 221 22
(90,110] 4 4 (90,110] 54 5 (90,110] 52 7 (90,110] 46 5
Median 72 IQR=(66, 80) Median 74 IQR=(67, 82) Median 75 IQR=(69, 83) Median 74 IQR=(68, 81) 
## Gender distribution ##
## DEC vs. drug ##
Characteristic % (n = 101) % (n = 1,000) Std.Diff Characteristic % (n = 101) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 3.0 2.1 -0.06
25 - 29 0 0.1 0.04 Visual system disorder 46.5 35.5 -0.23
30 - 34 1.0 1.0 0.00 Medical history: Cardiovascular disease
35 - 39 5.0 0.9 -0.24 Atrial fibrillation 40.6 26.2 -0.31
40 - 44 0 2.1 0.21 Cerebrovascular disease 18.8 9.1 -0.28
45 - 49 3.0 4.2 0.07 Coronary arteriosclerosis 41.6 30.3 -0.24
50 - 54 3.0 3.3 0.02 Heart disease 82.2 58.4 -0.54
55 - 59 5.0 4.2 -0.04 Heart failure 42.6 24.1 -0.40
60 - 64 5.0 3.4 -0.08 Ischemic heart disease 15.8 15.5 -0.01
65 - 69 17.8 13.3 -0.12 Peripheral vascular disease 41.6 26.5 -0.32
70 - 74 17.8 18.6 0.02 Pulmonary embolism 4.0 2.2 -0.10
75 - 79 16.8 15.9 -0.03 Venous thrombosis 8.9 6.9 -0.07
80 - 84 10.9 13.9 0.09 Medical history: Neoplasms
85 - 89 10.9 11.6 0.02 Hematologic neoplasm 9.9 7.1 -0.10
90 - 94 1.0 4.2 0.20 Malignant lymphoma 4.0 3.3 -0.04
95 - 99 3.0 2.3 -0.04 Malignant neoplasm of anorectum 1.0 1.0 0.00
100 - 104 0 1.0 0.14 Malignant neoplastic disease 41.6 24.4 -0.37
Gender: female 55.4 59.4 0.08 Malignant tumor of breast 7.9 3.3 -0.20
Medical history: General Malignant tumor of colon 5.9 2.9 -0.15
Acute respiratory disease 27.7 20.9 -0.16 Malignant tumor of lung 4.0 2.5 -0.08
Attention deficit hyperactivity disorder 2.0 0.4 -0.15 Malignant tumor of urinary bladder 4.0 1.5 -0.15
Chronic liver disease 5.0 3.2 -0.09 Medication use
Chronic obstructive lung disease 15.8 9.2 -0.20 Agents acting on the renin-angiotensin system 77.2 71.3 -0.14
Crohn’s disease 0 0.2 0.06 Antibacterials for systemic use 65.3 49.0 -0.33
Dementia 18.8 11.2 -0.21 Antidepressants 67.3 60.3 -0.15
Depressive disorder 24.8 9.7 -0.41 Antiepileptics 43.6 33.7 -0.20
Diabetes mellitus 73.3 52.1 -0.45 Antiinflammatory and antirheumatic products 38.6 33.3 -0.11
Gastroesophageal reflux disease 24.8 13.1 -0.30 Antineoplastic agents 18.8 10.0 -0.25
Gastrointestinal hemorrhage 6.9 6.1 -0.03 Antipsoriatics 1.0 0.6 -0.04
Human immunodeficiency virus infection 0 0.3 0.08 Antithrombotic agents 57.4 47.8 -0.19
Hyperlipidemia 36.6 22.5 -0.31 Beta blocking agents 77.2 71.4 -0.13
Hypertensive disorder 13.9 4.9 -0.31 Calcium channel blockers 58.4 56.1 -0.05
Lesion of liver 7.9 3.6 -0.19 Diuretics 74.3 67.3 -0.15
Obesity 10.9 5.8 -0.18 Drugs for acid related disorders 63.4 44.7 -0.38
Osteoarthritis 62.4 35.0 -0.57 Drugs for obstructive airway diseases 49.5 34.9 -0.30
Pneumonia 6.9 4.2 -0.12 Drugs used in diabetes 66.3 54.3 -0.25
Psoriasis 4.0 2.0 -0.12 Immunosuppressants 5.0 4.8 -0.01
Renal impairment 40.6 22.6 -0.39 Lipid modifying agents 81.2 73.6 -0.18
Rheumatoid arthritis 8.9 5.2 -0.15 Opioids 39.6 29.5 -0.21
Schizophrenia 5.0 6.6 0.07 Psycholeptics 59.4 51.8 -0.15
Ulcerative colitis 0 0.2 0.06 Psychostimulants, agents used for adhd and nootropics 17.8 14.7 -0.08
Urinary tract infectious disease 27.7 19.6 -0.19 
## Event vs. All ##
Characteristic % (n = 721) % (n = 1,000) Std.Diff Characteristic % (n = 721) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 1.9 1.3 -0.05
25 - 29 0.1 0.6 0.08 Visual system disorder 51.0 40.5 -0.21
30 - 34 0.8 0.9 0.01 Medical history: Cardiovascular disease
35 - 39 1.2 0.4 -0.09 Atrial fibrillation 39.9 27.7 -0.26
40 - 44 1.2 0.9 -0.03 Cerebrovascular disease 15.3 9.4 -0.18
45 - 49 1.9 3.1 0.07 Coronary arteriosclerosis 47.4 29.3 -0.38
50 - 54 2.2 2.4 0.01 Heart disease 81.0 57.6 -0.52
55 - 59 2.9 3.2 0.02 Heart failure 40.5 24.2 -0.35
60 - 64 4.4 2.9 -0.08 Ischemic heart disease 25.9 13.5 -0.32
65 - 69 13.9 15.4 0.04 Peripheral vascular disease 44.7 26.0 -0.40
70 - 74 18.3 23.2 0.12 Pulmonary embolism 3.6 2.9 -0.04
75 - 79 17.5 17.8 0.01 Venous thrombosis 12.8 8.7 -0.13
80 - 84 14.3 13.3 -0.03 Medical history: Neoplasms
85 - 89 11.7 9.6 -0.07 Hematologic neoplasm 12.8 9.2 -0.11
90 - 94 5.5 4.0 -0.07 Malignant lymphoma 5.0 4.0 -0.05
95 - 99 3.1 1.9 -0.07 Malignant neoplasm of anorectum 1.5 1.7 0.01
100 - 104 0.8 0.4 -0.06 Malignant neoplastic disease 38.7 27.2 -0.25
Gender: female 59.1 54.6 -0.09 Malignant tumor of breast 4.9 3.5 -0.07
Medical history: General Malignant tumor of colon 4.7 3.1 -0.08
Acute respiratory disease 37.9 21.8 -0.36 Malignant tumor of lung 6.5 4.2 -0.10
Attention deficit hyperactivity disorder 0.7 0.3 -0.06 Malignant tumor of urinary bladder 4.4 2.7 -0.09
Chronic liver disease 4.0 2.5 -0.09 Medication use
Chronic obstructive lung disease 19.7 9.6 -0.29 Agents acting on the renin-angiotensin system 49.4 0 -1.40
Crohn’s disease 1.5 0.4 -0.12 Antibacterials for systemic use 40.6 0 -1.17
Dementia 17.9 10.6 -0.21 Antidepressants 44.1 0 -1.26
Depressive disorder 14.1 8.3 -0.19 Antiepileptics 25.4 0 -0.82
Diabetes mellitus 71.2 48.2 -0.48 Antiinflammatory and antirheumatic products 23.4 0 -0.78
Gastroesophageal reflux disease 24.0 14.6 -0.24 Antineoplastic agents 15.8 0 -0.61
Gastrointestinal hemorrhage 9.8 6.1 -0.14 Antipsoriatics 0.6 0 -0.11
Human immunodeficiency virus infection 0.4 0.5 0.01 Antithrombotic agents 40.8 0 -1.17
Hyperlipidemia 33.1 25.5 -0.17 Beta blocking agents 43.0 0 -1.23
Hypertensive disorder 6.9 3.9 -0.13 Calcium channel blockers 34.8 0 -1.03
Lesion of liver 5.4 3.4 -0.10 Diuretics 45.5 0 -1.29
Obesity 9.3 5.4 -0.15 Drugs for acid related disorders 35.0 0 -1.04
Osteoarthritis 54.1 38.9 -0.31 Drugs for obstructive airway diseases 32.5 0 -0.98
Pneumonia 10.7 4.9 -0.22 Drugs used in diabetes 38.1 0 -1.11
Psoriasis 2.4 1.6 -0.05 Immunosuppressants 4.6 0 -0.31
Renal impairment 35.4 23.9 -0.25 Lipid modifying agents 47.6 0 -1.35
Rheumatoid arthritis 9.2 6.3 -0.11 Opioids 27.7 0 -0.88
Schizophrenia 8.0 4.0 -0.17 Psycholeptics 38.4 0 -1.12
Ulcerative colitis 0.6 0.3 -0.04 Psychostimulants, agents used for adhd and nootropics 11.2 0 -0.50
Urinary tract infectious disease 28.7 18.4 -0.24 
## Drug vs. All ##
Characteristic % (n = 721) % (n = 1,000) Std.Diff Characteristic % (n = 721) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 1.9 1.3 -0.05
25 - 29 0.1 0.6 0.08 Visual system disorder 51.0 40.5 -0.21
30 - 34 0.8 0.9 0.01 Medical history: Cardiovascular disease
35 - 39 1.2 0.4 -0.09 Atrial fibrillation 39.9 27.7 -0.26
40 - 44 1.2 0.9 -0.03 Cerebrovascular disease 15.3 9.4 -0.18
45 - 49 1.9 3.1 0.07 Coronary arteriosclerosis 47.4 29.3 -0.38
50 - 54 2.2 2.4 0.01 Heart disease 81.0 57.6 -0.52
55 - 59 2.9 3.2 0.02 Heart failure 40.5 24.2 -0.35
60 - 64 4.4 2.9 -0.08 Ischemic heart disease 25.9 13.5 -0.32
65 - 69 13.9 15.4 0.04 Peripheral vascular disease 44.7 26.0 -0.40
70 - 74 18.3 23.2 0.12 Pulmonary embolism 3.6 2.9 -0.04
75 - 79 17.5 17.8 0.01 Venous thrombosis 12.8 8.7 -0.13
80 - 84 14.3 13.3 -0.03 Medical history: Neoplasms
85 - 89 11.7 9.6 -0.07 Hematologic neoplasm 12.8 9.2 -0.11
90 - 94 5.5 4.0 -0.07 Malignant lymphoma 5.0 4.0 -0.05
95 - 99 3.1 1.9 -0.07 Malignant neoplasm of anorectum 1.5 1.7 0.01
100 - 104 0.8 0.4 -0.06 Malignant neoplastic disease 38.7 27.2 -0.25
Gender: female 59.1 54.6 -0.09 Malignant tumor of breast 4.9 3.5 -0.07
Medical history: General Malignant tumor of colon 4.7 3.1 -0.08
Acute respiratory disease 37.9 21.8 -0.36 Malignant tumor of lung 6.5 4.2 -0.10
Attention deficit hyperactivity disorder 0.7 0.3 -0.06 Malignant tumor of urinary bladder 4.4 2.7 -0.09
Chronic liver disease 4.0 2.5 -0.09 Medication use
Chronic obstructive lung disease 19.7 9.6 -0.29 Agents acting on the renin-angiotensin system 49.4 0 -1.40
Crohn’s disease 1.5 0.4 -0.12 Antibacterials for systemic use 40.6 0 -1.17
Dementia 17.9 10.6 -0.21 Antidepressants 44.1 0 -1.26
Depressive disorder 14.1 8.3 -0.19 Antiepileptics 25.4 0 -0.82
Diabetes mellitus 71.2 48.2 -0.48 Antiinflammatory and antirheumatic products 23.4 0 -0.78
Gastroesophageal reflux disease 24.0 14.6 -0.24 Antineoplastic agents 15.8 0 -0.61
Gastrointestinal hemorrhage 9.8 6.1 -0.14 Antipsoriatics 0.6 0 -0.11
Human immunodeficiency virus infection 0.4 0.5 0.01 Antithrombotic agents 40.8 0 -1.17
Hyperlipidemia 33.1 25.5 -0.17 Beta blocking agents 43.0 0 -1.23
Hypertensive disorder 6.9 3.9 -0.13 Calcium channel blockers 34.8 0 -1.03
Lesion of liver 5.4 3.4 -0.10 Diuretics 45.5 0 -1.29
Obesity 9.3 5.4 -0.15 Drugs for acid related disorders 35.0 0 -1.04
Osteoarthritis 54.1 38.9 -0.31 Drugs for obstructive airway diseases 32.5 0 -0.98
Pneumonia 10.7 4.9 -0.22 Drugs used in diabetes 38.1 0 -1.11
Psoriasis 2.4 1.6 -0.05 Immunosuppressants 4.6 0 -0.31
Renal impairment 35.4 23.9 -0.25 Lipid modifying agents 47.6 0 -1.35
Rheumatoid arthritis 9.2 6.3 -0.11 Opioids 27.7 0 -0.88
Schizophrenia 8.0 4.0 -0.17 Psycholeptics 38.4 0 -1.12
Ulcerative colitis 0.6 0.3 -0.04 Psychostimulants, agents used for adhd and nootropics 11.2 0 -0.50
Urinary tract infectious disease 28.7 18.4 -0.24 
## Top drugs and conditions for DEC ##
drugs_180_days n_180_days
beta blocking agents 156
antithrombotic agents 116
cardiovascular system 100
alimentary tract and metabolism 96
nervous system 95
antiepileptics 88
respiratory system 84
lipid modifying agents 82
lipid modifying agents, plain 82
agents acting on the renin-angiotensin system 78
analgesics 76
hmg coa reductase inhibitors 76
diuretics 75
psychoanaleptics 73
antihistamines for systemic use 70
sensory organs 70
antiinfectives for systemic use 69
blood and blood forming organs 69
ophthalmologicals 69
antidepressants 68
systemic hormonal preparations, excl. sex hormones and insulins 68
drugs used in diabetes 67
ace inhibitors, plain 66
ace inhibitors, plain 66
all other therapeutic products 66
cond_180_days n_180_days
arthropathy 85
inflammation of specific body systems 84
heart disease 83
inflammation of specific body organs 77
pain 76
diabetes mellitus 74
pain finding at anatomical site 74
vascular disorder 70
measurement finding outside reference range 69
type 2 diabetes mellitus 69
pain of truncal structure 67
soft tissue lesion 66
degenerative disorder of musculoskeletal system 63
osteoarthritis 63
neoplastic disease 59
musculoskeletal and connective tissue disorder 56
abnormal blood cell count 55
cardiac arrhythmia 55
measurement finding below reference range 54
anemia 53
cytopenia 53
erythropenia 53
hemoglobin level outside reference range 53
hemoglobin low 53
rbc count abnormal 53